Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 19/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 13/20 | 1.00 |
| ▸ | CCNA1 | P78396 | 13/20 | 1.00 |
| ▸ | CDK5 | Q00535 | 3/20 | 1.00 |
| ▸ | CCNE1 | P24864 | 2/20 | 1.00 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 1.00 |
| ▸ | CCNB2 | O95067 | 1/20 | 1.00 |
| ▸ | CCNE2 | O96020 | 1/20 | 1.00 |
| ▸ | CDK1 | P06493 | 1/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 1/20 | 1.00 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 1.00 |
| ▸ | CDK9 | P50750 | 2/20 | 0.67 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25225939 | 0.95 | CDK2 (0.91) | CDK2CCNA2CCNA1CDK5CCNE1 | |
| SCHEMBL6387681 | 0.95 | CDK2 (0.91) | CDK2CCNA2CCNA1CDK5CCNE1 | |
| SCHEMBL6389529 | 0.94 | CDK2 (0.89) | CDK2CCNA2CCNA1CDK5CCNE1 | |
| SCHEMBL5867728 | 0.91 | CDK2 (0.84) | CDK2CCNA2CCNA1CDK5CCNE1 | |
| SCHEMBL5867444 | 0.90 | CDK2 (0.81) | CDK2CCNA2CCNA1CDK5CCNE1 | |
| SCHEMBL6386299 | 0.88 | CDK2 (0.78) | CDK2CCNA2CCNA1CDK5CCNE1 | |
| SCHEMBL5867719 | 0.87 | CDK2 (1.00) | CDK2CCNA2CCNA1CDK5CCNE1 | |
| SCHEMBL6389757 | 0.85 | CDK2 (0.72) | CDK2CCNA2CCNA1CDK5CCNE1 | |
| SCHEMBL5867579 | 0.85 | CDK2 (1.00) | CDK2CCNA2CCNA1CDK5CCNE1 | |
| SCHEMBL5867666 | 0.83 | CDK2 (0.72) | CDK2CCNA2CCNA1CDK5CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1202733-B1 | 3(5)-AMINO-PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA ITALIA SPA (IT) | 2005-10-05 | — | — | EP | claimed |
| EP-1202733-A4 | 3(5)-AMINO-PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA ITALIA SPA (IT) | 2003-05-14 | — | — | EP | claimed |
| JP-2003507329-A | — | — | 2003-02-25 | — | — | JP | claimed |
| EP-1202733-A1 | 3(5)-AMINO-PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | Pharmacia Italia S.p.A. (IT) | 2002-05-08 | — | — | EP | claimed |
| WO-2001012189-A1 | 3(5)-AMINO-PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA ITALIA S.P.A. (IT) | 2001-02-22 | — | — | WO | claimed |
| US-7034049-B1 | 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents | PHARMACIA ITALIA S.P.A. (IT) | 2006-04-25 | — | — | US | disclosed |
| EP-1202733-B1 | 3(5)-AMINO-PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA ITALIA SPA (IT) | 2005-10-05 | — | — | EP | disclosed |
| CN-1454091-A | Immunostimulatory nucleic acids | UNIV IOWA RES FOUND (US) | 2003-11-05 | — | — | CN | disclosed |
| EP-1202733-A4 | 3(5)-AMINO-PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA ITALIA SPA (IT) | 2003-05-14 | — | — | EP | disclosed |
| CN-1373662-A | 3(5)-amino-pyrazole derivs., process for their preparation and their use as antitumor agents | PHARMACIA & UP JOHN S P A (IT) | 2002-10-09 | — | — | CN | disclosed |
| EP-1202733-A1 | 3(5)-AMINO-PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | Pharmacia Italia S.p.A. (IT) | 2002-05-08 | — | — | EP | disclosed |
| WO-2001012189-A1 | 3(5)-AMINO-PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA ITALIA S.P.A. (IT) | 2001-02-22 | — | — | WO | disclosed |